Emergence of 16S rRNA methylase-producing Acinetobacter baumannii and Pseudomonas aeruginosa isolates in hospitals in Vietnam

Table 1 MIC50 and MIC90 values and percent antimicrobial resistance for A. baumannii and P. aeruginosa clinical isolates

Antimicrobial agent		A. baumannii(n = 101)				P. aeruginosa(n = 15)
Antimicrobial agent	Breakpoint forresistance^a(mg/L)	%Resistance	Range(mg/L)	MIC₅₀(mg/L)	MIC₉₀(mg/L)	Breakpoint forresistance^a(mg/L)	%Resistance	Range(mg/L)	MIC₅₀(mg/L)	MIC₉₀(mg/L)
Amikacin	≥64	85	<2- > 1024	>1024	>1024	≥64	60	<2- > 1024	64	>1024
Arbekacin	-	-	<2- > 1024	>1024	>1024	-	-	2- > 1024	2	>1024
Aztreonam	-	-	<2- > 256	128	>256	≥32	46	4- > 256	16	>256
Ceftazidime	≥32	55	<4- > 512	>512	>512	≥32	46	<4- > 512	16	>512
Ciprofloxacin	≥4	98	<1- > 128	128	>128	≥4	66	<1-64	8	32
Colistin	≥4	6	<0.25-4	2	2	≥8	0	<0.25-0.5	<0.25	0.5
Gentamicin	≥16	91	<2- > 1024	>1024	>1024	≥16	66	<2- > 1024	256	>1024
Imipenem	≥16	48	<4-128	16	32	≥8	53	<4-64	16	32
Meropenem	≥16	51	<4- > 256	32	64	≥8	53	<4-32	16	32
Piperacillin	≥128	100	<4- > 512	>512	>512	≥128	46	<4- > 512	32	256
Piperacillin/Tazobactam	≥128/4	52	<4- > 512	256	512	≥128/4	13	<4-512	32	128

^aBreakpoints for antimicrobial resistance were determined according to the guidelines of the Clinical and Laboratory Standards Institute (M07-A9).

ISSN: 1471-2334